Year |
Citation |
Score |
2019 |
Yu H, Janssen JM, Sawicki E, van Hasselt JGC, de Weger VA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development. Journal of Clinical Pharmacology. PMID 31595980 DOI: 10.1002/Jcph.1532 |
0.503 |
|
2017 |
Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. S22-S26. PMID 28502674 DOI: 10.1016/j.ejps.2017.05.022 |
0.318 |
|
2016 |
Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. British Journal of Clinical Pharmacology. PMID 27161955 DOI: 10.1111/Bcp.13007 |
0.684 |
|
2016 |
Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. European Journal of Cancer (Oxford, England : 1990). 54: 120-130. PMID 26761784 DOI: 10.1016/J.Ejca.2015.10.013 |
0.707 |
|
2015 |
van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 386-95. PMID 26312162 DOI: 10.1002/psp4.49 |
0.577 |
|
2015 |
van Hasselt J, Gupta A, Hussein Z, Beijnen JH, Schellens J, Huitema A. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. Cpt: Pharmacometrics & Systems Pharmacology. 4: 374-85. PMID 26312161 DOI: 10.1002/psp4.48 |
0.607 |
|
2015 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". Biomed Research International. 2015: 124035. PMID 25922829 DOI: 10.1155/2015/124035 |
0.705 |
|
2015 |
Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Hooiveld MJ, Neven P, Raaijmakers JA, Schellens JH. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. European Journal of Cancer Care. 24: 340-54. PMID 25413216 DOI: 10.1111/Ecc.12266 |
0.391 |
|
2015 |
Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology. 79: 809-19. PMID 25393890 DOI: 10.1111/Bcp.12550 |
0.724 |
|
2015 |
Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated with Eribulin Cpt: Pharmacometrics and Systems Pharmacology. 4: 386-395. DOI: 10.1002/psp4.49 |
0.448 |
|
2015 |
Van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM, Huitema ADR. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment with Eribulin Cpt: Pharmacometrics and Systems Pharmacology. 4: 374-385. DOI: 10.1002/psp4.48 |
0.434 |
|
2014 |
van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatric Blood & Cancer. 61: 2223-9. PMID 25175364 DOI: 10.1002/Pbc.25198 |
0.705 |
|
2014 |
van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Investigational New Drugs. 32: 913-27. PMID 24788562 DOI: 10.1007/S10637-014-0103-8 |
0.71 |
|
2014 |
van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2059-65. PMID 24713311 DOI: 10.1093/Annonc/Mdu140 |
0.58 |
|
2014 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Research International. 2014: 897216. PMID 24672799 DOI: 10.1155/2014/897216 |
0.73 |
|
2014 |
Frederix GW, van Hasselt JG, Schellens JH, Hövels AM, Raaijmakers JA, Huitema AD, Severens JL. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 32: 47-61. PMID 24263964 DOI: 10.1007/S40273-013-0106-X |
0.692 |
|
2013 |
Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Raaijmakers JA, Schellens JH. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 139: 489-95. PMID 23645005 DOI: 10.1007/S10549-013-2532-Z |
0.384 |
|
2013 |
van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. British Journal of Clinical Pharmacology. 76: 412-24. PMID 23601153 DOI: 10.1111/Bcp.12143 |
0.744 |
|
2013 |
van Hasselt JG, van Eijkelenburg NK, Huitema AD, Schellens JH, Schouten-van Meeteren AY. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrobial Agents and Chemotherapy. 57: 2878-81. PMID 23571545 DOI: 10.1128/Aac.00068-13 |
0.671 |
|
2013 |
Frederix GW, van Hasselt JG, Severens JL, Hövels AM, Huitema AD, Raaijmakers JA, Schellens JH. Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 780-92. PMID 23515213 DOI: 10.1177/0272989X13476763 |
0.657 |
|
2013 |
Van Hasselt JGC, van Eijkelenburg NKA, Beijnen JH, Schellens JHM, Huitema ADR. Optimizing drug development of anti-cancer drugs in children using modelling and simulation British Journal of Clinical Pharmacology. 76: 30-47. PMID 23216601 DOI: 10.1111/Bcp.12062 |
0.476 |
|
2013 |
Mallaysamy S, Johnson MG, Rao PGM, Rajakannan T, Bathala L, Arumugam K, Van Hasselt JGC, Ramakrishna D. Population pharmacokinetics of lamotrigine in Indian epileptic patients European Journal of Clinical Pharmacology. 69: 43-52. PMID 22660444 DOI: 10.1007/s00228-012-1311-9 |
0.315 |
|
2012 |
Van Hasselt JGC, Schellens JHM, Mac Gillavry MR, Beijnen JH, Huitema ADR. Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab Pharmaceutical Research. 29: 3499-3511. PMID 22907417 DOI: 10.1007/S11095-012-0845-Y |
0.473 |
|
2012 |
van Hasselt JG, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema AD. Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. Journal of Palliative Care. 28: 60-1. PMID 22582474 |
0.689 |
|
2012 |
van Hasselt JC, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema A. Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer Journal of Palliative Care. 28: 60-61. DOI: 10.1177/082585971202800110 |
0.53 |
|
2011 |
van den Broek MP, Huitema AD, van Hasselt JG, Groenendaal F, Toet MC, Egberts TC, de Vries LS, Rademaker CM. Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures. Clinical Pharmacokinetics. 50: 461-9. PMID 21651313 DOI: 10.2165/11589160-000000000-00000 |
0.669 |
|
2011 |
Van Hasselt JGC, Boekhout AH, Beijnen JH, Schellens JHM, Huitema ADR. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab- associated cardiotoxicity Clinical Pharmacology and Therapeutics. 90: 126-132. PMID 21633346 DOI: 10.1038/Clpt.2011.74 |
0.511 |
|
Show low-probability matches. |